Unicycive Therapeutics, Inc.
UNCY · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $3 | $2 | $2 | $5 |
| G&A Expenses | $4 | $5 | $6 | $4 |
| SG&A Expenses | $4 | $5 | $6 | $4 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $7 | $7 | $8 | $9 |
| Operating Income | -$7 | -$7 | -$8 | -$9 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1 | $1 | $9 | -$12 |
| Pre-Tax Income | -$6 | -$6 | $1 | -$22 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$6 | -$6 | $1 | -$22 |
| % Margin | – | – | – | – |
| EPS | -0.33 | -0.52 | 0.044 | -2 |
| % Growth | 36.5% | -1,281.8% | 102.2% | – |
| EPS Diluted | -0.33 | -0.52 | -0.502 | -2 |
| Weighted Avg Shares Out | 18 | 12 | 12 | 7 |
| Weighted Avg Shares Out Dil | 18 | 12 | 12 | 7 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$6 | -$6 | $1 | -$9 |
| % Margin | – | – | – | – |